secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001213900-23-098726
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay initiates SYMON multicenter study of Symphony IL-6 test in sepsis patients
--------------------------------------------------------------------------------

- Study will monitor IL-6 in sepsis/septic shock patients admitted to ICU; aims to predict 28-day mortality.
- Study design incorporates feedback from pre-submission meetings with the FDA held earlier in 2023.
- Symphony System delivers results from whole blood in ~20 minutes; study listed on clinicaltrials.gov (NCT06181604).
- CEO Neil Dey says study moves company 'one step closer to commercialization' and may identify competitive advantages.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023098726/0001213900-23-098726-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023098726/ea190739-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-098726

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer